These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19367171)

  • 1. Efficacy of insulin glargine in perioperative glucose control in type 2 diabetic patients.
    Kang H; Ahn KJ; Choi JY; Park HJ; Park SJ; Lee SK
    Eur J Anaesthesiol; 2009 Aug; 26(8):666-70. PubMed ID: 19367171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
    King AB
    Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of glargine insulin on glycemic control in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft.
    Gandhi H; Sarvaia A; Malhotra A; Acharya H; Shah K; Rajavat J
    Ann Card Anaesth; 2018; 21(2):167-172. PubMed ID: 29652278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H; Dressler A; Ziemen M;
    Diabetes Care; 2000 Aug; 23(8):1130-6. PubMed ID: 10937510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in inpatient glycemic control and response to subcutaneous insulin therapy between medicine and surgery patients with type 2 diabetes.
    Smiley D; Umpierrez GE; Hermayer K; Newton C; Jacobs S; Olson DE; Khan A; Rizzo M; Peng L; Reyes D; Cardona S; Fonseca V
    J Diabetes Complications; 2013; 27(6):637-41. PubMed ID: 23911535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.
    Bretzel RG; Nuber U; Landgraf W; Owens DR; Bradley C; Linn T
    Lancet; 2008 Mar; 371(9618):1073-84. PubMed ID: 18374840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes.
    Hanefeld M; Koehler C; Hoffmann C; Wilhelm K; Kamke W; Gerstein H
    Diabet Med; 2010 Feb; 27(2):175-80. PubMed ID: 20546261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Perioperative glycemic control by insulin glargine in type 2 diabetic patients].
    Li NS; Li WH; Wang H
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Feb; 30(1):109-11. PubMed ID: 18361065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
    Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
    Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J; Park G; Zimmerman J;
    Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F; Carabino JM; Vergara CM
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
    Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
    Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ; Gylvin T; DeLuzio T; Raskin P
    Endocr Pract; 2011; 17(1):41-50. PubMed ID: 20713345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Optimised glycaemic control and dose titration with insulin glargine (Lantus) by general practitioners in Switzerland: results of the OPTI-LAN Postmarketing Study].
    Spirk D; Lareida J; Scheidegger K; Diem P
    Praxis (Bern 1994); 2009 Mar; 98(6):315-20. PubMed ID: 19291638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes.
    Roach P; Malone JK
    Diabet Med; 2006 Jul; 23(7):743-9. PubMed ID: 16842478
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin Glargine: a review 8 years after its introduction.
    Goykhman S; Drincic A; Desmangles JC; Rendell M
    Expert Opin Pharmacother; 2009 Mar; 10(4):705-18. PubMed ID: 19284367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P; Pampanelli S; Fanelli C; Porcellati F; Costa E; Torlone E; Scionti L; Bolli GB
    Diabetes Care; 2003 May; 26(5):1490-6. PubMed ID: 12716810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.